Genmab Launches DKK 725 Million Share Buy-Back to Cover RSU Commitments

robot
Abstract generation in progress

Genmab, a global biotech company specializing in antibody-based cancer therapies, initiated a share buy-back program worth DKK 725 million. This program, running from February 18 to March 31, 2026, aims to cover obligations under its Restricted Stock Unit scheme and manage share dilution. The company plans to repurchase up to 342,130 shares, adding to its existing treasury shares.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)